Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

OBJECTIVES: The aim of this study is to determine whether the ‘programmed’ infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontin...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Rheum Dis
Главные авторы: Tanaka, Yoshiya, Oba, Koji, Koike, Takao, Miyasaka, Nobuyuki, Mimori, Tsuneyo, Takeuchi, Tsutomu, Hirata, Shintaro, Tanaka, Eiichi, Yasuoka, Hidekata, Kaneko, Yuko, Murakami, Kosaku, Koga, Tomohiro, Nakano, Kazuhisa, Amano, Koichi, Ushio, Kazuyasu, Atsumi, Tatsuya, Inoo, Masayuki, Hatta, Kazuhiro, Mizuki, Shinichi, Nagaoka, Shouhei, Tsunoda, Shinichiro, Dobashi, Hiroaki, Horie, Nao, Sato, Norihiro
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Rheumatoid Arthritis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6937411/
https://ncbi.nlm.nih.gov/pubmed/31630117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216169
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы